CAPRICOR THERAPEUTICS, INC.

CAPR

Held by 2 specialist biotech funds

Share on X

Fund Holdings

RA Capital Management RTW Investments

AI Signal

AI analyst context — unlock full analysis

Catalysts

No catalysts tracked.

Position Details

RA Capital ManagementNEWFeb 17, 2026

Shares: 1,507,844Value: $43.5M

# Signal Note: RA Capital Initiates $43.5M Position in Capricor RA Capital's entry into CAPR signals conviction in CAP-1002, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy (DMD) and acute myocarditis. The $43.5M stake (1.5M shares) arrives ahead of potential regulatory inflection points, likely including DMD trial readouts or manufacturing scale-up data that could validate the cell therapy platform's commercial viability.

RTW InvestmentsNEWFeb 17, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

TSHA2 funds PCSC2 funds EVMN2 funds FDMT2 funds JBIO2 funds GHRS2 funds SYRE2 funds WVE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

**Signal Note: RTW Investments Initiates $7.2M Position in Capricor (CAPR)** RTW's $7.2M entry into CAPR suggests conviction in the company's lead program, CAP-1002 (allogeneic cardiosphere-derived cells) for Duchenne muscular dystrophy (DMD), which completed Phase 2b dosing in 2023 with interim data expected near-term. The timing aligns with potential catalysts from ongoing DMD studies and the company's pivot toward heart failure indications, where cell therapy demand remains clinically underexplored.